MRNA Moderna (MRNA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001682852
Congress · 1Form 144 · 7
Insider buyers, 180 days
0
Funds added, last quarter
404
13F, latest reported quarter
Conversions, 180 days
46
Codes C/M, not in net · $22.2M priced
What the filings say about MRNA
Insiders, 180 days
-$72.4M net sold
6 sellers · 44% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-09-24
Planned sales (Form 144), 90 days
$62.8M
7 notices
Moderna insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Moderna, Inc. insiders sold a net $72.4M of stock across 1,466 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 243 earlier Form 4 trades (code P or S) here by this insider (243 sales), the last on Oct 14, 2026.
- The trade is 2.4% of the 1,636,565 shares held after it.
- No other insider sold within 30 days.
- 404 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hoge Stephen sold about $8.6M of MRNA under a 10b5-1 plan on Oct 15, 2026; 404 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 15, 2026.
- The trade is 2.4% of the 1,599,708 shares held after it.
- No other insider sold within 30 days.
- 404 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hoge Stephen sold about $8.3M of MRNA under a 10b5-1 plan on Oct 14, 2026; 404 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 15, 2026.
- The trade is 0.0% of the 1,599,258 shares held after it.
- No other insider sold within 30 days.
- 404 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hoge Stephen sold about $96.4K of MRNA under a 10b5-1 plan on Oct 14, 2026; 404 funds added in the latest 13F quarter.Context
- 240 earlier Form 4 trades (code P or S) here by this insider (240 sales), the last on Sep 14, 2026.
- The trade is 2.6% of the 1,562,029 shares held after it.
- 2 other insiders sold within 30 days.
- 404 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hoge Stephen sold about $5.9M of MRNA under a 10b5-1 plan on Sep 15, 2026; 2 other insiders sold within 30 days and 404 funds added in the latest 13F quarter.Context
- 239 earlier Form 4 trades (code P or S) here by this insider (239 sales), the last on Jul 15, 2026.
- The trade is 2.6% of the 1,525,858 shares held after it.
- 2 other insiders sold within 30 days.
- 404 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hoge Stephen sold about $5.8M of MRNA under a 10b5-1 plan on Sep 14, 2026; 2 other insiders sold within 30 days and 404 funds added in the latest 13F quarter.1,466 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$72.4M over 180 days
-$62.6M over 90 days
below 96% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
404 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
-39.9% year over year
below 77% of Pharma & Biotech
Margin
-145.2% net margin
below 61% of Pharma & Biotech
Buybacks
$2.0M repurchased, FY to 2025-12-31
below 86% of Pharma & Biotech
Short interest
8.3% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
more than 63% of Pharma & Biotech
What changed in the last 30 days
Oct 16President Hoge Stephen sold $17.0M under a 10b5-1 plan (3 trades, Oct 14 to Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer Hoge Stephen filed to sell $8.6M by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 14Officer Hoge Stephen filed to sell $8.4M by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 7Rep. Maria Elvira Salazar sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch MRNA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+645.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRNA: institutional holders (13F)
13F holdings, latest reported quarter
51,859,891 sh
$3.6B
30,599,409 sh
$2.1B
23,208,792 sh
$1.6B
22,276,996 sh
$1.6B
18,206,778 sh
$1.3B
Congress trades in MRNA
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-24 · disclosed 13 days later
$1,001 - $15,000
Sold 2026-08-19 · disclosed 21 days later
$1,001 - $15,000
Bought 2026-08-19 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Bought 2025-02-25 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MRNA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Hoge Stephen
Filed 2026-10-15
$8.6M
Hoge Stephen
Filed 2026-10-14
$8.4M
Hoge Stephen
Filed 2026-09-15
$5.9M
Hoge Stephen
Filed 2026-09-14
$5.8M
Mock James M
Filed 2026-09-10
$4.7M
MRNA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
REX IncomeMax Option Strategy ETF
$1.9M position · as of 2026-06-30
4.8%
iShares Genomics Immunology and Healthcare ETF
$8.0M position · as of 2026-07-31
4.2%
Adaptiv Select ETF
$6.2M position · as of 2026-07-31
3.5%
VanEck Biotech ETF
$13.3M position · as of 2026-06-30
3.4%
Global X Genomics & Biotechnology ETF
$1.8M position · as of 2026-05-31
3.3%
iShares Health Innovation Active ETF
$326.1K position · as of 2026-07-31
2.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Bancel
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$19.9M
$15.8M
$9.8M
-72%
+20%
2024
$19.9M
$5.8M
$14.6M
-60%
-9%
2023
$17.1M
-$155.6M
$5.1M
-5%
-8%
2022
$19.4M
-$306.2M
$5.8M
+72%
-11%
2021
$18.2M
$793.0M
$8.3M
+143%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $72.4M sold by insiders over 180 days, 404 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $62.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MRNA financials
Revenue growth
-39.9%
XBRL, annual
Net margin
-145.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MRNA
| FY Dec 2025 | $1.9B |
| FY Dec 2024 | $3.2B |
| FY Dec 2023 | $6.8B |
| FY Dec 2022 | $19.3B |
| FY Dec 2021 | $18.5B |
| Jun 2026 | $145.0M |
| Mar 2026 | $389.0M |
| Dec 2025 | $678.0M |
| Sep 2025 | $1.0B |
| Jun 2025 | $142.0M |
| Mar 2025 | $108.0M |
| Dec 2024 | $966.0M |
| Sep 2024 | $1.9B |
At each fiscal year end
Single quarter
Net margin, TTM
-141.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MRNA
| FY Dec 2025 | -145.2% |
| FY Dec 2024 | -110.0% |
| FY Dec 2023 | -68.8% |
| FY Dec 2022 | +43.4% |
| FY Dec 2021 | +66.1% |
| Jun 2026 | -539.3% |
| Mar 2026 | -345.2% |
| Dec 2025 | -121.8% |
| Sep 2025 | -19.7% |
| Jun 2025 | -581.0% |
| Mar 2025 | -899.1% |
| Dec 2024 | -115.9% |
| Sep 2024 | +0.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$1.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MRNA
| FY Dec 2025 | -$2.1B |
| FY Dec 2024 | -$4.1B |
| FY Dec 2023 | -$3.8B |
| FY Dec 2022 | $4.6B |
| FY Dec 2021 | $13.3B |
| Jun 2026 | -$563.0M |
| Mar 2026 | -$692.0M |
| Dec 2025 | $891.0M |
| Sep 2025 | -$880.0M |
| Jun 2025 | -$922.0M |
| Mar 2025 | -$1.2B |
| Dec 2024 | $303.0M |
| Sep 2024 | -$1.7B |
At each fiscal year end
Single quarter
Debt to equity
0.09x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity MRNA
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.82x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt MRNA
| FY Dec 2025 | -3.17x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.82x |
| Mar 2026 | -2.48x |
| Dec 2025 | -3.17x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-39.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MRNA
| FY Dec 2025 | -28.9% |
| FY Dec 2024 | -28.8% |
| FY Dec 2023 | -28.6% |
| FY Dec 2022 | +50.3% |
| FY Dec 2021 | +146.1% |
| Jun 2026 | -39.0% |
| Mar 2026 | -36.6% |
| Dec 2025 | -28.9% |
| Sep 2025 | -29.3% |
| Jun 2025 | -27.5% |
| Mar 2025 | -29.3% |
| Dec 2024 | -28.8% |
| Sep 2024 | -17.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-27.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MRNA
| FY Dec 2025 | -21.3% |
| FY Dec 2024 | -21.9% |
| FY Dec 2023 | -21.3% |
| FY Dec 2022 | +33.1% |
| FY Dec 2021 | +76.2% |
| Jun 2026 | -27.4% |
| Mar 2026 | -26.4% |
| Dec 2025 | -21.3% |
| Sep 2025 | -22.3% |
| Jun 2025 | -21.0% |
| Mar 2025 | -22.8% |
| Dec 2024 | -21.9% |
| Sep 2024 | -12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MRNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-35.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MRNA
| FY Dec 2025 | -27.6% |
| FY Dec 2024 | -28.9% |
| FY Dec 2023 | -23.3% |
| FY Dec 2022 | +51.7% |
| FY Dec 2021 | +143.8% |
| Jun 2026 | -35.2% |
| Mar 2026 | -33.8% |
| Dec 2025 | -27.6% |
| Sep 2025 | -28.8% |
| Jun 2025 | -27.6% |
| Mar 2025 | -29.3% |
| Dec 2024 | -28.9% |
| Sep 2024 | -18.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MRNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 8.98x |
| FY Dec 2021 | 8.98x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$78.8B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value MRNA
| FY Dec 2025 | $9.5B |
| FY Dec 2024 | $14.1B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $26.7B |
| Mar 2026 | $18.7B |
| Dec 2025 | $9.5B |
| Sep 2025 | $8.9B |
| Jun 2025 | $9.4B |
| Mar 2025 | $9.3B |
| Dec 2024 | $14.1B |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.6%
TTM free cash flow over market value at close 2026-10-23
FCF yield MRNA
| FY Dec 2025 | -17.9% |
| FY Dec 2024 | -25.3% |
| FY Dec 2023 | -10.1% |
| FY Dec 2022 | +6.6% |
| FY Dec 2021 | +13.0% |
| Jun 2026 | -4.5% |
| Mar 2026 | -8.0% |
| Dec 2025 | -17.9% |
| Sep 2025 | -26.4% |
| Jun 2025 | -32.7% |
| Mar 2025 | -36.8% |
| Dec 2024 | -25.3% |
| Sep 2024 | -15.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MRNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.9B | $3.2B | $6.8B | $19.3B |
| Operating income | -$3.1B | -$3.9B | -$4.2B | $9.4B |
| Net income | -$2.8B | -$3.6B | -$4.7B | $8.4B |
| EPS (diluted) | -7.26 | -9.28 | -12.33 | 20.12 |
| Operating cash flow | -$1.9B | -$3.0B | -$3.1B | $5.0B |
| Cash | $2.6B | $1.9B | $2.9B | $3.2B |
| Long-term debt | $590.0M | $0 | n/a | n/a |
| Buybacks | $2.0M | $0 | $1.2B | $3.3B |
SEC XBRL, fiscal years, as known on 2026-10-27
MRNA Stock Sonar score 6/7 axes
Find similar shapesCompareMRNA ranks highest on institutional and government (68th percentile) and profitability (63rd), and lowest on insider conviction (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRNA filings, in plain words
Are Moderna insiders buying or selling MRNA?
In the 180 days to 2026-10-27, Moderna insiders were net sellers, a net $72.4M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded MRNA?
Yes. In the year to 2026-10-27, 1 House member disclosed buying MRNA and 1 House member disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24.
Are there planned insider sales of MRNA?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $62.8M of stock; the latest, by Hoge Stephen, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, Moderna insiders were net sellers of MRNA, a net $72.4M across purchases and sales reported on Form 4 by 6 sellers. 44% of the 18 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying MRNA and 1 member disclosed selling it; the latest on record is a sale by Maria Elvira Salazar dated 2026-09-24. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $62.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
